On 4 November 2026, a Chinese drug developer announced that it had licensed HP570 — an oral VAV1 molecular glue degrader being developed for autoimmune disease — to US-listed biotech Evommune for every market except Greater China (announcement, in Chinese). For a patient living with a chronic autoimmune condition and weighing the options for treatment in China, the interesting part is not the headline valuation. It is what the deal leaves behind. Because China development stays with the originator, the first human data and the first registration filing for this molecule are likely to be Chinese ones. That means the dates worth putting in a calendar are the China IND decision and the start of the Phase 1 study — not a future FDA letter.
This article explains how the split-rights structure works, which milestones an international patient should actually monitor, and what the realistic contact points are for someone who needs long-term therapy rather than a news story.
What the HP570 announcement confirms — and what it does not
The disclosed terms are worth reading precisely, because patients routinely over-read this kind of press release.
- Scope of the licence: all HP570 rights outside Greater China, granted exclusively to Evommune and its wholly owned subsidiary Evommune MGD. Greater China rights remain with the Chinese originator (listed on the Shanghai Stock Exchange STAR Market under code 688302).
- Consideration: total potential payments of up to US$1.1 billion, made up of US$30 million in upfront consideration — US$20 million in cash and US$10 million in warrants exercisable at US$0.0001 per share — plus up to US$1.07 billion in development, regulatory and commercialisation milestones, with tiered royalties and a share of sublicensing income.
- Development status: an investigational new drug application in the United States has been cleared by the FDA. In China, the IND is still under regulatory review, and a Phase 1 clinical trial is described as about to start.
- The partner: Evommune is listed on the New York Stock Exchange under ticker EVMN and is headquartered in Palo Alto, California.
Equally important is the list of things the announcement does not state. There is no confirmed trial start date, no published site list, no eligibility criteria, no endpoints, no projected approval date, and no price. A licence deal of this shape also says nothing about efficacy — a molecular glue degrader at IND stage is a molecule that is allowed to be tested, not one that has been shown to work. Keep that distinction in mind every time a figure like "US$1.1 billion" appears next to a drug name, because it is the maximum value of conditional payments, not a valuation of clinical success.
Why keeping Greater China rights changes the order of events
Out-licensing is normally read as a signal about the US or European market. When the licensor keeps Greater China, the reading order flips for anyone considering access to new drugs in China.
The mechanics
Three practical consequences follow from the retained-rights structure:
- The China programme is run by the originator. Protocol design, site selection and the eventual local registration filing sit with the Chinese company rather than an overseas partner. The China IND review and the China Phase 1 are therefore the earliest publicly trackable events for this molecule.
- Regulatory clocks run independently. A cleared US IND does not accelerate a Chinese review, and a Chinese decision does not depend on what Evommune later reports. Progress in one jurisdiction is not evidence of progress in the other.
- Commercial rights are geographically split. Whatever the eventual label, pricing, distribution and hospital formulary decisions in Greater China and in the rest of the world will be made by different companies, on different commercial logic, at different times.
The honest caveat is that "China-first" is a possibility created by the rights structure, not a guarantee. Most candidates at IND stage do not reach any market, and oral autoimmune agents have a demanding safety bar precisely because they are intended for long-term use in non-terminally-ill patients.
The two clocks, side by side
| Milestone to track | Status as disclosed on 5 Nov 2026 | Where to verify it | What it tells an international patient |
|---|---|---|---|
| US IND | Cleared by the FDA | FDA / company disclosures | A US trial may begin; says nothing about availability |
| China IND | Under review | China regulatory announcements | The gate for anything clinical in China; still pending |
| China Phase 1 | About to start | Clinical trial registry entries once published | The first real data point, and the first moment enrolment questions become concrete |
| Registration filing | Not mentioned | Regulator decision notices | Years away; treat all speculation as noise |
| Price / reimbursement | Not mentioned | Hospital quotation and local reimbursement lists | Ask for an actual quote; do not budget against media estimates |
Reading the table the right way
The rows are ordered by probability, not by importance. The IND rows are near-certain to resolve soon because they are administrative; the registration row is where most programmes are lost. For someone considering medical tourism to China on the strength of a molecule like this, the correct action at the IND-review stage is preparation, not travel.
Access routes for a patient who needs long-term therapy
If you live with an autoimmune condition that typically requires continuous treatment — inflammatory arthritis, lupus, bowel or skin disease — the practical question is never "is this drug famous?" but "when can I be prescribed something, by whom, and at what cost?" Four routes exist, in very different states of readiness.
| Route | Earliest realistic contact | Evidence maturity | What you must prepare | Continuity risk |
|---|---|---|---|---|
| Current approved therapy in your home country | Now | Established | Insurance or self-pay arrangements | Low, but limited if you have already failed the available options |
| An already-registered therapy available in China | After an in-person outpatient evaluation | Established in its approved indication | Translated records, appointment, visa, admission documents | Supply and follow-up planning across borders |
| A clinical trial such as a future HP570 study | Only after the study is registered and recruiting | Investigational | Protocol-eligible disease status, medication washout, ability to attend scheduled visits on site | High: eligibility is decided by the protocol, not by a booking |
| Expanded or off-label use | Case-by-case, at physician discretion | Variable | Detailed treatment history and signed informed consent | High: responsibility for monitoring stays with your treating physician |
For the second route, China's regulatory environment can genuinely shorten the gap between "published" and "prescribed" in some therapeutic areas — which is why our broader guide to medical tourism to China treats availability, evidence and logistics as three separate questions. For the third route, the most useful thing to do now is build the paperwork that any trial team will ask for anyway: a clinical summary letter, recent laboratory results, imaging, pathology where relevant, and a dated history of every disease-modifying drug you have taken, with doses and reasons for stopping.
Two constraints deserve plain language. First, an investigational oral agent is not a fallback for someone who cannot access their current biologic; trials usually require you to stop existing therapy, which is a medical decision and not a scheduling one. Second, receiving care as a foreign patient in China requires being physically present for the visit schedule and arranging follow-up before you leave, which is why hospital appointment support in Shanghai and China's medical visa process are logistics to solve in advance rather than on arrival.
A useful comparison in the same news cycle: ivonescimab
The other China-origin story circulating this week shows what a later stage looks like. Ivonescimab — a PD-1 × VEGF bispecific antibody developed by China's Akeso and partnered with Summit Therapeutics — has a PDUFA decision date of 14 November 2026 for EGFR-mutated, locally advanced or metastatic non-squamous non-small-cell lung cancer after progression on a third-generation TKI, according to a daily biopharma briefing. The filing, accepted by the FDA in January 2026, rests on the global phase 3 HARMONi trial: 438 patients, median progression-free survival of 6.8 months with the combination plus chemotherapy versus 4.4 months with chemotherapy alone, and a 48% relative reduction in the risk of progression or death (HR 0.52, 95% CI 0.41–0.66, p<0.0001).
Two lessons transfer to autoimmune patients watching HP570. A regulator's decision date is a real, trackable event, whereas trial-stage announcements mostly are not — so weight them differently. And an approval in one market does not automatically resolve access, pricing or referral pathways in another; the questions that remain are which hospitals stock the medicine, what they actually charge, and what documentation they require from overseas patients. Our cancer treatment in China service handles exactly those questions for oncology patients, and the same logic applies to chronic disease.
What to watch, and what to do now
A short monitoring list, in order of information value:
- Confirmation that the China IND has been cleared for review completion, followed by a Phase 1 study appearing in a public trial registry with named sites and stated inclusion criteria.
- The first safety and pharmacodynamic read-out, which tells you whether an oral VAV1 degrader behaves as intended in humans at all.
- Milestone payments disclosed by either party, because those are triggered by actual progress rather than by optimism.
- Any regulatory filing for a China indication, which — unlike everything above — would be a genuine access event.
Until item four exists, the rational position for a patient is neutral: continue or optimise currently available therapy, keep records in order, and treat this molecule as one to watch rather than one to plan around. If your situation involves refractory disease, intolerance to current medication, or a specialist system in China you want evaluated — including which hospitals and departments run relevant autoimmune programmes — that is a case-specific question, and it is answerable today.
Any specific treatment plan must be assessed in person by a licensed physician based on your diagnosis, disease activity and comorbidities. Nothing in this article is medical advice or a prediction of approval, availability or outcome.
Next step: submit your records for a case evaluation so a clinician can tell you whether a China-based pathway is worth pursuing, or send a question through our inquiry page. OriEast supports patients with certified record translation, outpatient appointment booking at tertiary and international departments, visa and itinerary planning, on-the-ground interpretation and coordination of follow-up before you travel home.